ABSTRACT-Endotoxin is an important pathogenic trigger for sepsis. The polymyxin B-immobilized endotoxin removal hemoperfusion cartridge, Toraymyxin (hereafter PMX), has been shown to remove endotoxin in preclinical and open-label clinical studies. In a multicenter, open-label, pilot, randomized, controlled study conducted in the intensive care unit in six academic medical centers in Europe, 36 postsurgical patients with severe sepsis or septic shock secondary to intraabdominal infection were randomized to PMX treatment of 2 h (n = 17) or standard therapy (n = 19). PMX was well tolerated and showed no significant side effects. There were no statistically significant differences in the change in endotoxin levels from baseline to 6 to 8 h after treatment or to 24 h after treatment between the two groups. There was also no significant difference in the change in interleukin (IL)-6 levels from baseline to 6 to 8 h after treatment or to 24 h after treatment between the two groups. Patients treated with PMX demonstrated significant increases in cardiac index (CI; P = 0.012 and 0.032 at days 1 and 2, respectively), left ventricular stroke work index (LVSWI, P = 0.015 at day 2), and oxygen delivery index (DO 2 I, P = 0.007 at day 2) compared with the controls. The need for continuous renal replacement therapy (CRRT) after study entry was reduced in the PMX group (P = 0.043). There was no significant difference between the groups in organ dysfunction as assessed by the Sequential Organ Failure Assessment (SOFA) scores from day 0 (baseline) to day 6. Treatment using the PMX cartridge is safe and may improve cardiac and renal dysfunction due to sepsis or septic shock. Further studies are needed to prove this effectiveness.
INTRODUCTION
Sepsis and septic shock continue to be life-threatening complications and major causes of death in the medical and surgical intensive care unit (ICU). In the last decade, research into the pathogenesis and pathophysiology of sepsis, septic shock, and subsequent multiple organ failure (MOF) has clarified some of the mechanisms of these disease processes (1) (2) (3) (4) . Various mediators, including cytokines, nitric oxide (NO), reactive oxygen species, and lysosomal enzymes, are liberated by activation of leukocytes, macrophages, and endothelial cells, and are thought to play a pivotal role in the pathophysiology of septic shock and MOF. Hemodynamics in patients with sepsis or septic MOF may be improved with continuous hemofiltration (CHF) or continuous hemodiafiltration (CHDF), possibly due to the removal of some of these humoral mediators (5) , and the addition of coupled plasma filtration adsorption to hemodialysis may be more effective at improving hemodynamic status in patients with sepsis than hemodialysis alone (6) .
The PMX cartridge (Toraymyxin, Toray Industries, Tokyo, Japan) is an extracorporeal hemoperfusion device that uses polymyxin-B fixed to a-chloroacetamide-methyl polystyrenederived fibers that are packed in the cartridge. Polymyxin-B is chemically immobilized in the polystyrene-derived fiber through covalent bonds and does not leach from the fiber. Polymyxin-B is known to bind to endotoxin, an outer membrane component of gram-negative bacteria that is thought to be an important pathogenic trigger for the production of inflammatory mediators. Several preclinical studies demonstrated that hemoperfusion or plasmapheresis over immobilized polymyxin-B could remove endotoxin from the blood (7) (8) (9) . Subsequently, open-label clinical trials using PMX were conducted in Japan, demonstrating the safety of PMX in the treatment of septic shock and its capacity to decrease endotoxin levels (10) . More recent studies have shown improved hemodynamic status (11) and improved survival (12) in patients with sepsis treated with PMX. Since 1994, PMX has been listed as a blood purification device in Japan and is reimbursed by Japanese national health insurance. The PMX device received its product certification (CE mark) for use in Europe, according to the directives of the European Community in 1998, and is classified as a Class IIb medical device.
In a recent randomized phase II trial (13) of another hemofiltration endotoxin-adsorbing system, based on immobilized human serum albumin, no significant differences in endotoxin elimination or organ function (as assessed by the Sequential Organ Failure Assessment [SOFA]) were identified between treated patients and controls, although there was a trend to improved renal function and shorter length of ICU stay in the subgroup of treated patients with peritonitis.
The current study is the first prospective randomized controlled trial (RCT) of the PMX device in patients with sepsis. The hypothesis was that, in line with previous in vitro and clinical studies, treatment with PMX would reduce endotoxin levels and improve hemodynamic status. To increase homogeneity in the study population, we included only patients with sepsis of abdominal origin.
PATIENTS AND METHODS
Six European, academic medical centers were involved in the study. The ethics committees for each center approved the study protocol. Informed consent was obtained from each patient or the patient's relative or surrogate.
Study population
The study population consisted of surgical patients with severe sepsis (with or without shock) presumed to be caused by gram-negative infection, arising from the abdominal cavity, and still present after surgery. Patients who had initially undergone elective surgery were eligible if the PMX treatment could be started within 24 h of diagnosis of severe sepsis. Patients admitted to hospital for intraabdominal infection requiring emergency surgery were also eligible provided the PMX treatment was started within 48 h of diagnosis of severe sepsis. Inclusion criteria were presumed gram-negative infection arising from the abdominal cavity within 2 weeks of abdominal surgery, at least two of the systemic inflammatory response syndrome (SIRS) criteria (14) , and at least one organ dysfunction defined as follows: cardiovascular-systolic blood pressure of below 90 mmHg (11.7 kPa) or a decrease in systolic blood pressure of at least 40 mmHg from baseline, which was transient or required treatment with vasoactive drugs at any dose; respiratory-PaO 2 of less than 75 mmHg (9.75 kPa) or PaO 2 /FiO 2 ratio of less than 250 mmHg; renal-creatinine of more than 2 mg/dL (171 mmol/L) or urine output of less than 500 mL/day or a urine output of less than 30 mL/h for 2 h during patient screening; coagulation-a 50% decrease in platelet count or a decrease in the platelet count to less than 100 3 10 3 /mm 3 ; central nervous system (CNS)-Glasgow Coma Scale of less than 13 or decrease of greater than 1 from baseline; and hepatic-bilirubin of more than 10 mg/dL. Patients were excluded from the study for the following reasons: life expectancy less than 30 days (as assessed by the attending physician); ''do not resuscitate'' order; HIV infection; uncontrolled hemorrhage within 24 h before study entry; organ transplantation during the year before study entry; history of sensitivity to polymyxin-B or anticoagulant and/or extracorporeal circulation; severe thrombocytopenia (<30,000 cells/mm 3 ) and/or granulocytopenia (<500 cells/mm 3 ); an APACHE II score (15) >30, a SOFA score (16) >12 or >4 organ failures by Goris score (17); and end-stage organ failure defined as follows: respiratory-end-stage chronic obstructive airways disease and corpulmonale; cardiac-New York Heart Association score = IV; CNS-brain stem death (confirmed by the attending physician and an independent physician registered for more than 5 years, on two separate occasions) or persistent vegetative state; renalrequiring maintenance hemodialysis; hepatic-chronic liver disease complicated by hepatic encephalopathy, coagulopathy, fluid retention, and/or hepatocellular jaundice. Patients without evidence of gram-negative infection or endotoxemia at baseline were excluded from the analysis at the end of the study (patients with only gram-positive or fungal cultures were kept in the final study analysis as long as a significant endotoxin level had been measured).
Treatment
Patients who fulfilled the study criteria were randomized, using sealed envelopes, to receive standard therapy plus PMX (PMX group) or standard therapy only (control group). Patients of both groups received full intensive care management, including fluid resuscitation, vasopressors, antimicrobial therapy, ventilatory support, appropriate surgical management (including drainage of the nidus of infection), and continuous renal replacement therapy (CRRT) and hemodialysis, if required. PMX hemoperfusion was conducted in the ICU. All patients in the PMX group underwent PMX treatment only once, on day 0, after severe sepsis had been diagnosed. For venous access, a double lumen catheter was inserted into the femoral vein and blood was drawn from the vein and returned to it. The blood flow rate was permitted to be no less than 80 mL/min and no greater than 120 mL/min, according to the study protocol. Each individual session of hemoperfusion lasted for 2 h. Heparin was used as an anticoagulant. The activated clotting time was measured (0, 30, 90, and 120 min) and the heparin infusion was adjusted, if needed, to keep the activated clotting time within the range of 180 to 240 s. A hemofiltration machine, or a direct hemoperfusion machine with a heparin pump and monitors for inlet and outlet pressure, was used for PMX hemoperfusion. When the hemoperfusion was discontinued within the first 90 min of treatment due to clotting problems, a second PMX treatment was considered. Patients whose PMX treatments were discontinued within 90 min of the second treatment were withdrawn from the study. However, all data were included in the intention to treat analysis.
Study procedures
Patients were followed up for 28 days. All patients had a pulmonary artery catheter inserted as part of routine management. In each patient, the following hemodynamic and blood gas variables were assessed at baseline, day 1, and day 2: heart rate (HR), mean arterial pressure (MAP), right atrial pressure (RAP), pulmonary arterial pressure (PAP), pulmonary capillary wedge pressure (PCWP), cardiac index (CI), systemic vascular resistance (SVR), left ventricular stroke work index (LVSWI), oxygen delivery index (DO 2 I), oxygen consumption index (VO 2 I), and PaO 2 /FiO 2 (P/F ratio). The following were also recorded during the study: routine observations (body temperature, HR, mean blood pressure, and respiratory rate), general blood chemistry/hematology for safety assessment, urine output, concomitant devices and medication, bacteriology, length of ICU stay, and survival. Organ dysfunction was assessed using the SOFA and Goris scores. Endotoxin and IL-6 levels were measured at baseline, 120 min (post-treatment and PMX group only), 6 to 8 h, and 24 h after the first blood sampling. All endotoxin and IL-6 assays were done at a central laboratory (Hammersmith Hospital, London, UK). IL-6 was measured using a commercial kit (Quantikine, R & D Systems, Minneapolis, MN), and endotoxin was measured with the modified limulus amebocyte lysate (LAL) assay (18) using a commercial kit (COATEST, Diapharma, West Chester, OH). The LAL assay is highly sensitive (0.005 EU/mL in saline; 0.05 EU/mL in serum or plasma) and is virtually specific for endotoxin.
Outcome measurements
The primary endpoint was improvement of organ dysfunction in patients and was assessed by the changes in the SOFA score and Goris score from baseline at day 1 to day 6. Secondary endpoints were reduction in plasma endotoxin and IL-6 concentrations (pretreatment to 120 min, 6-8 h and 24 h post-treatment), patient survival over 28 days after PMX treatment, and length of ICU stay. After data analysis, the outcome of the study was not as expected, and due to this, an additional analysis was performed on the hemodynamic data, comparing the change from baseline to day 1 and day 2; the pulmonary artery catheter enabling hemodynamic measurements was present in the majority of patients for up to 2 days post-treatment. Also, the need for renal replacement therapy was assessed for the first 5 days after study entry.
Data analysis
Efficacy and safety analyses were performed on a per protocol analysis. The change from baseline was compared between the two groups using an analysis of covariance (ANCOVA) or nonparametric test (Wilcoxon test). The normal distribution of the data was checked using the Shapiro-Wilk's test and a normal QQ-plot. When the data were normally distributed, the Student's t test was used. Wilcoxon test was used for the data that were not normally distributed. The endotoxin and IL-6 levels were compared using the Wilcoxon test. For the changes in hemodynamic and blood gas data, the data were compared using ANCOVA. For SOFA and Goris scores, the mean area under the curve from baseline to day 6 was calculated. The total scores were carried forward for patients who died before day 6. Shock-free days were defined as the number of days a subject was alive and not receiving vasopressor medication during the 28-day period. Mechanical ventilation (MV)-free days and ICU-free days were calculated likewise. The difference in the free days between the two groups was compared by a Student's t test. The two groups were also compared for frequency of initiation of CRRT using a Fisher's exact test. Patient survival over the 28 days was assessed by product-limit life table analyses using the log-rank test. Hypothesis tests were two sided and at the 5% level of statistical significance.
RESULTS

Baseline demographics
A total of 36 patients were randomly assigned into the study over 2 years, with 17 patients in the PMX group and 19 patients in the control group. One patient, in the control group, was excluded from analysis (as per protocol) for not showing evidence of a gram-negative infection or endotoxemia at baseline. The demographics and baseline data of the 35 patients remaining in the analysis are summarized in Table 1 . There was no significant difference between the two groups in baseline demographics, APACHE II score, or number of failed organs.
Gram-negative bacteria were detected between day 24 and day 0 (baseline) in 13 (72%) control and 14 (82%) PMX patients; seven of the control and 10 of the PMX patients were infected with mixed bacteria (Table 1 ). In the control group, four of 18 patients had gram-negative bacteremia. In the PMX group, three of 17 patients had gram-negative bacteremia. There were no significant differences in antibiotic administration at baseline (Table 1) .
Endotoxin and IL-6
The median, 25% percentile, and 75% percentile of blood endotoxin and IL-6 levels are shown in Table 2 . The baseline endotoxin and IL-6 levels were similar in both groups.
Endotoxin levels in both groups did not change significantly between baseline and 120 min. There were no statistically significant differences in the endotoxin levels between the two groups at any time point. IL-6 levels in both groups showed a tendency to decrease after 24 h, but this was not statistically significant.
Hemodynamic and blood gas data
Changes in hemodynamic variables from baseline to days 1 and 2 were evaluated. There were no significant differences in hemodynamic variables at baseline between the groups (Table  3 ). In the PMX group, MAP increased significantly from baseline to day 2 (P = 0.006). In the control group, PAPs increased significantly from baseline to day 1 (P = 0.034) and day 2 (P = 0.004). CI was significantly greater in the PMX than in the control group at days 1 and 2 (P = 0.012 and 0.032). In the PMX group, the LVSWI increased from baseline to day 2 and was greater than in the control group on day 2 (P = 0.015). The PCWP remained unchanged (Fig. 1) . DO 2 I increased in the PMX group to become significantly greater than in the control group on day 2 (P = 0.007).
At baseline, 14 (78%) control and 17 (100%) PMX patients were receiving at least one inotropic agent (Table 1 ). There were no significant differences between groups in the doses of each inotropic or vasopressive agent on days 1 and 2. There was no significant difference in shock-free days (control: 15.2 ± 11.1, range 0-29 days; PMX: 14.4 ± 12.5 days, range 0-28 days).
Organ function
The mean serum creatinine value at baseline was similar in both groups (control, 2.03 ± 0.96 mg/dL; PMX, 1.94 ± 1.03 mg/dL). Nine (50%) of 18 control patients and 8 (47%) of 17 PMX patients had renal failure (oliguria or creatinine >2 mg/dL) at study entry, and a total of seven (39%) control patients and two (12%) PMX patients received CRRT (hemofiltration including CVVH and/or hemodialysis) for the first 5 days of the study. The frequency of CRRT initiation after study entry in the control group (seven of 18 cases with an average CRRT duration of 9.3 days) was statistically greater (P = 0.043) than in the PMX group (one of 16 cases [one patient was already receiving CRRT at baseline] with a duration of 1 day only).
At baseline, 16 (89%) control and 17 (100%) PMX patients were already receiving MV. The mean number of MV-free days was 13.9 ± 11.3 days in the PMX group and 11.7 ± 10.7 days in the control group (differences not significant). There were no significant differences in the SOFA and Goris Scores between the control and the PMX groups.
Survival over 28 days and time in ICU
Five of 18 (28%) control patients and five of 17 (29%) PMX patients died during the study period. The survival analysis of time (days) to death showed no statistical significance between the two groups (P = 0.749). There was no statistically significant difference in the mean duration of ICU stay between the two groups (PMX, 13.2 ± 9.4 days; control, 17.0 ± 9.4 days, ns). The number of ICU-free days was 6.8 ± 9.4 and 9.2 ± 10.4 days in the control and PMX groups, respectively (ns). 402 SHOCK VOL. 23, NO. 5
Adverse events
During the study, all patients in both groups reported at least one treatment-emergent adverse events (AE). The control group patients had a greater number of AEs than the PMX patients (control, 127 events [7.1 per patient]; PMX, 80 events [4.7 per patient]). Only one PMX patient had a treatmentemergent AE considered to be possibly device related (fever). The most frequent AEs that occurred during the study were pleural effusions (five control and three PMX patients), anemia (three control and four PMX patients), and fluid overload (three patients in each group). None of the AEs occurred during PMX treatment, and the AEs reported during the study were not indicative of polymyxin-B toxicity (nephrotoxicity, including albuminuria and cellular casts; neurotoxicity, including irritability and progressive weakness).
There were no significant differences in the white blood cell or platelet counts between the two groups. Twelve (71%) PMX patients received PMX treatment within 48 h after abdominal surgery. Despite the administration of 2500 to 7000 U of unfractionated heparin (bolus plus continuous administration), no AEs due to bleeding were observed during or after PMX treatment.
Device failure
A total of 21 PMX cartridges were used for 17 patients in the PMX group. Four (24%) of 17 treatments were incomplete at the first attempt due to clotting. Two of these cases were successfully treated with an additional cartridge. In the other two patients, the second treatment was not completed because clotting occurred again after 51 and 34 min, respectively. At this point, these two patients were withdrawn from the study; however, their data were included in the intention to treat analysis.
DISCUSSION
This is the first multicenter RCT using PMX hemoadsorption in severe sepsis or septic shock. The results indicated that CI, LVSWI, and DO 2 I were significantly improved in the PMX group. The need for CRRT was also decreased in the PMX group, and the device was proven to be safe.
PMX is a hemoperfusion cartridge designed to remove endotoxin from the patient's circulation. During this pilot study, there was no significant change in endotoxin levels in the PMX group (at 120 min), but the endotoxin levels showed significant variability within the two groups at each time point measured and across time. This degree of variability may confound the assessment of the PMX device, but is entirely consistent with other clinical studies using the LAL assay to measure plasma endotoxin levels in critically ill patients (19) (20) (21) (22) . The LAL assay is highly sensitive (0.005 EU/mL in saline; 0.05 EU/mL in serum or plasma) and is virtually specific for endotoxin. Although activated by b-glucan, a component of fungal cell walls, this has to be present in extremely high concentrations before it affects the assay and, therefore, has not been felt to be a confounding factor in the many clinical studies that have evaluated the LAL test. The inability to show a significant decrease in endotoxin levels has been described previously in Japanese clinical studies using this device (23) . Furthermore, patients in this study were treated with PMX up to 48 h after the diagnosis of severe sepsis and this also may have affected the endotoxin results. In addition, PMX was applied to patients only once in this study. In cases with overwhelming endotoxin invasion into the blood stream, one session of hemoperfusion with PMX might not be enough. More frequent treatments may have been more effective. In this pilot study, there was no limitation to ICU patient management apart from the endotoxin adsorption therapy, and differences in infusion therapy among centers may have influenced the hemodynamic results. However, any such effects would be the same in the placebo and PMX groups, thus minimizing any influence on comparisons between groups. In addition, CRRT may have an affect on hemodynamics. Hirasawa et al. (5) reported that hemodynamics in patients with sepsis or septic MOF were improved by the removal of a variety of humoral mediators, including IL-6, with CHF or CHDF. In the present study, there was no significant difference in IL-6 levels between the groups.
Several experimental studies have reported beneficial hemodynamic effects of PMX. In a canine model of endotoxininduced shock, Aoki et al. (24) investigated the cardiovascular improvement with hemoperfusion carried out using PMX, a sham cartridge (carrier fiber without polymyxin-B), charcoal, and an anion exchange resin; only the PMX-treated group demonstrated an increase in blood pressure. In a later canine study (25) , PMX was compared with a sham treatment (blood tubing only) and an anion exchange resin; only the PMX group experienced a sustained increase in blood pressure. In a recent sheep model, PMX improved systemic hemodynamics and oxygenation compared with treatment with a sham column (26) . In open-label, nonrandomized clinical studies in Japan, PMX treatment has been associated with earlier withdrawal from dopamine infusion, as a result of increased MAP and increased SVR (CI unchanged) (27, 28) . In the present RCT, MAP in the PMX group also increased significantly from baseline to day 2, but there was no significant difference between the two groups. An improvement in cardiac function by PMX was indicated in this study by an increase in LVSWI without notable changes in PCWP.
The favorable effects of PMX on cardiac function may be secondary to the elimination of myocardial-depressant mediators. Various candidates have been suggested. Recently, Nakamura et al. (29) reported that cardiac troponin T levels, a potential marker of septic myocardial injury (30), were higher in hemodialysis patients with sepsis than in those without sepsis and healthy control subjects, and that PMX treatment reduced these levels (29) . Other possible candidates that may be removed by PMX treatment with resulting beneficial hemodynamic effects include endogenous cannabinoids, such as macrophage-derived anandamide (31) and tetrahydrbiopterin, an essential cofactor for inducible nitric oxide synthase (32) . Further clinical studies are needed to investigate the exact mechanisms involved in PMX treatment.
We acknowledge the study has some limitations, including potential confounding effects of the heparin used in the hemoperfusion device, the limitations of the assays used to measure endotoxin and IL-6 levels, and the inability to measure all mediators or constituents that may have been removed by the cartridge.
In conclusion, although this pilot study failed to demonstrate reduced blood endotoxin levels compared with the control group, the results do show that PMX treatment is safe, and is associated with an improved hemodynamic status and cardiac function. Larger, adequately powered, multicenter clinical trials now need to be conducted to confirm the effects of PMX treatment on hemodynamics and to determine its effects on outcome.
